Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

There is only one GLP-1 pill on the market, and it's not as effective as Ozempic for weight loss.Grace Cary/Getty Images Eli Lilly competitor Novo Nordisk kicked off the weight-loss drug craze ...

Here are the small steps they're taking this year to get there. Eli Lilly's oral weight loss pill, orforglipron Eli Lilly competitor Novo Nordisk kicked off the weight-loss drug craze when it ...

BI Illustration Eli Lilly makes the popular shots Mounjaro and Zepbound. Next, the company says they have a pill coming that could be as powerful as rival Ozempic. The company's head of obesity said ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...